Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: An expert panel position paper
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F16%3A00060030" target="_blank" >RIV/00023001:_____/16:00060030 - isvavai.cz</a>
Result on the web
<a href="http://www.sciencedirect.com/science/article/pii/S0167527316315972" target="_blank" >http://www.sciencedirect.com/science/article/pii/S0167527316315972</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ijcard.2016.07.202" target="_blank" >10.1016/j.ijcard.2016.07.202</a>
Alternative languages
Result language
angličtina
Original language name
Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: An expert panel position paper
Original language description
Levosimendan is a positive inotrope with vasodilating properties (inodilator) indicated for decompensated heart failure (HF) patients with low cardiac output. Accumulated evidence supports several pleiotropic effects of levosimendan beyond inotropy, the heart and decompensated HF. Those effects are not readily explained by cardiac function enhancement and seem to be related to additional properties of the drug such as anti-inflammatory, anti-oxidative and anti-apoptotic ones. Mechanistic and proof-of-concept studies are still required to clarify the underlying mechanisms involved, while properly designed clinical trials are warranted to translate preclinical or early-phase clinical data into more robust clinical evidence. The present position paper, derived by a panel of 35 experts in the field of cardiology, cardiac anesthesiology, intensive care medicine, cardiac physiology, and cardiovascular pharmacology from 22 European countries, compiles the existing evidence on the pleiotropic effects of levosimendan, identifies potential novel areas of clinical application and defines the corresponding gaps in evidence and the required research efforts to address those gaps. (C) 2016 The Authors. Published by Elsevier Ireland Ltd.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
International journal of cardiology
ISSN
0167-5273
e-ISSN
—
Volume of the periodical
222
Issue of the periodical within the volume
1 November
Country of publishing house
IE - IRELAND
Number of pages
10
Pages from-to
303-312
UT code for WoS article
000384698300056
EID of the result in the Scopus database
—